Insmed Inc (INSM)
68.17
-0.15
(-0.22%)
USD |
NASDAQ |
Nov 04, 16:00
68.45
+0.28
(+0.41%)
After-Hours: 20:00
Insmed Research and Development Expense (Annual): 571.01M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 571.01M |
| December 31, 2022 | 397.52M |
| December 31, 2021 | 272.74M |
| December 31, 2020 | 181.16M |
| December 31, 2019 | 131.71M |
| December 31, 2018 | 145.28M |
| December 31, 2017 | 109.75M |
| December 31, 2016 | 122.72M |
| December 31, 2015 | 74.28M |
| December 31, 2014 | 56.29M |
| December 31, 2013 | 44.28M |
| December 31, 2012 | 29.78M |
| December 31, 2011 | 28.62M |
| Date | Value |
|---|---|
| December 31, 2010 | 4.702M |
| December 31, 2009 | 9.207M |
| December 31, 2008 | 21.05M |
| December 31, 2007 | 18.94M |
| December 31, 2006 | 21.09M |
| December 31, 2005 | 21.84M |
| December 31, 2004 | 23.32M |
| December 31, 2003 | 7.14M |
| December 31, 2002 | 18.08M |
| December 31, 2001 | 35.51M |
| December 31, 2000 | 21.61M |
| December 31, 1999 | 5.657M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
131.71M
Minimum
2019
571.01M
Maximum
2023
310.83M
Average
272.74M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Fulcrum Therapeutics Inc | 71.80M |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Eli Lilly and Co | 9.313B |
| Bioventus Inc | 13.45M |
| Entrada Therapeutics Inc | 99.88M |